Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
Seung Tae Kim, Tae Won Kim, Kyu-pyo Kim, Tae-You Kim, Sae-Won Han, Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Young Suk Park
Cancer Res Treat. 2015;47(4):790-795. Published online 2014 Dec 2 DOI: https://doi.org/10.4143/crt.2014.126
Citations to this article as recorded by 
Metastatik Kolorektal Kanserde Kurtarma Tedavisi:Regorafenib
Havva Yesil Cinkir
SDÜ Tıp Fakültesi Dergisi.2021;[Epub] CrossRef
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
Maria Røed Skårderud, Anne Polk, Kirsten Kjeldgaard Vistisen, Finn Ole Larsen, Dorte Lisbet Nielsen
Cancer Treatment Reviews.2018; 62: 61. CrossRef
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong
Ka-On Lam, Kin-Chung Lee, Joanne Chiu, Victor Ho-Fun Lee, Roland Leung, T S Choy, Thomas Yau
Postgraduate Medical Journal.2017; 93(1101): 395. CrossRef
Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
Molecular and Clinical Oncology.2017; 6(1): 63. CrossRef
Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Bin Zhao, Hong Zhao
Oncotarget.2017; 8(55): 93813. CrossRef
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Clinical Medicine Insights: Oncology.2016; 10: CMO.S38335. CrossRef